TET2 gene loss may indirectly cause several hematological malignancies, including myeloid, T cell and B cell cancers.
Is frequently mutated or deleted in myeloid malignancies, including acute myeloid leukemias, B cell non-Hodgkin lymphomas, chronic myelomonocytic leukemias, and myelodysplastic disorders
TET2 mutations found in 5%of healthy people older than 70 years.
Loss associated with hematopoietic stem cell self renewable and hematopoietic progenitor cell activity.